HEADER TRANSFERASE 30-OCT-05 2C5O
TITLE DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2
TITLE 2 PROVIDES INSIGHTS FOR DRUG DESIGN
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2;
COMPND 3 CHAIN: A, C;
COMPND 4 SYNONYM: CYCLIN-DEPENDENT KINASE 2, P33 PROTEIN KINASE;
COMPND 5 EC: 2.7.1.37;
COMPND 6 ENGINEERED: YES;
COMPND 7 OTHER_DETAILS: TRIAZOL-1-METHYL-PYRIMIDIN INHIBITOR;
COMPND 8 MOL_ID: 2;
COMPND 9 MOLECULE: CYCLIN A2;
COMPND 10 CHAIN: B, D;
COMPND 11 SYNONYM: CYCLIN A;
COMPND 12 ENGINEERED: YES
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 3 ORGANISM_COMMON: HUMAN;
SOURCE 4 ORGANISM_TAXID: 9606;
SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA;
SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108;
SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS;
SOURCE 8 MOL_ID: 2;
SOURCE 9 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 10 ORGANISM_COMMON: HUMAN;
SOURCE 11 ORGANISM_TAXID: 9606;
SOURCE 12 EXPRESSION_SYSTEM: ESCHERICHIA COLI;
SOURCE 13 EXPRESSION_SYSTEM_TAXID: 562
KEYWDS DIFFERENTIAL INHIBITION, TRANSFERASE, CDK2, ATP-BINDING, CELL CYCLE,
KEYWDS 2 CELL DIVISION, POLYMORPHISM, PHOSPHORYLATION, NUCLEOTIDE-BINDING,
KEYWDS 3 SERINE/THREONINE-PROTEIN, KINASE, MITOSIS, CYCLIN
EXPDTA X-RAY DIFFRACTION
AUTHOR G.KONTOPIDIS,C.MCINNES,S.R.PANDALANENI,I.MCNAE,D.GIBSON,M.MEZNA,
AUTHOR 2 M.THOMAS,G.WOOD,S.WANG,M.D.WALKINSHAW,P.M.FISCHER
REVDAT 3 13-DEC-23 2C5O 1 REMARK
REVDAT 2 24-FEB-09 2C5O 1 VERSN
REVDAT 1 01-MAR-06 2C5O 0
JRNL AUTH G.KONTOPIDIS,C.MCINNES,S.R.PANDALANENI,I.MCNAE,D.GIBSON,
JRNL AUTH 2 M.MEZNA,M.THOMAS,G.WOOD,S.WANG,M.D.WALKINSHAW,P.M.FISCHER
JRNL TITL DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE
JRNL TITL 2 CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN.
JRNL REF CHEM.BIOL. V. 13 201 2006
JRNL REFN ISSN 1074-5521
JRNL PMID 16492568
JRNL DOI 10.1016/J.CHEMBIOL.2005.11.011
REMARK 2
REMARK 2 RESOLUTION. 2.10 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : REFMAC 5.1.24
REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER,
REMARK 3 : NICHOLLS,WINN,LONG,VAGIN
REMARK 3
REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 22.00
REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL
REMARK 3 COMPLETENESS FOR RANGE (%) : 89.1
REMARK 3 NUMBER OF REFLECTIONS : 67904
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT
REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK 3 R VALUE (WORKING + TEST SET) : 0.197
REMARK 3 R VALUE (WORKING SET) : 0.195
REMARK 3 FREE R VALUE : 0.256
REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.000
REMARK 3 FREE R VALUE TEST SET COUNT : 2114
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : 20
REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.10
REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.15
REMARK 3 REFLECTION IN BIN (WORKING SET) : 3098
REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL
REMARK 3 BIN R VALUE (WORKING SET) : 0.2490
REMARK 3 BIN FREE R VALUE SET COUNT : 91
REMARK 3 BIN FREE R VALUE : 0.2980
REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 PROTEIN ATOMS : 8920
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 28
REMARK 3 SOLVENT ATOMS : 725
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : NULL
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 36.45
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : -2.08000
REMARK 3 B22 (A**2) : 0.23000
REMARK 3 B33 (A**2) : 1.85000
REMARK 3 B12 (A**2) : 0.00000
REMARK 3 B13 (A**2) : 0.00000
REMARK 3 B23 (A**2) : 0.00000
REMARK 3
REMARK 3 ESTIMATED OVERALL COORDINATE ERROR.
REMARK 3 ESU BASED ON R VALUE (A): 0.248
REMARK 3 ESU BASED ON FREE R VALUE (A): 0.213
REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.165
REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 6.574
REMARK 3
REMARK 3 CORRELATION COEFFICIENTS.
REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.946
REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.911
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT
REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9212 ; 0.012 ; 0.022
REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL
REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12513 ; 2.246 ; 1.969
REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL
REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1105 ; 8.388 ; 5.000
REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): NULL ; NULL ; NULL
REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): NULL ; NULL ; NULL
REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): NULL ; NULL ; NULL
REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1411 ; 0.178 ; 0.200
REMARK 3 GENERAL PLANES REFINED ATOMS (A): 6864 ; 0.012 ; 0.020
REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL
REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 4842 ; 0.293 ; 0.600
REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL
REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL
REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL
REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 1030 ; 0.280 ; 0.500
REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL
REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL
REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL
REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 79 ; 0.354 ; 0.600
REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL
REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 24 ; 0.457 ; 0.500
REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL
REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL
REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL
REMARK 3
REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT
REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5555 ; 1.703 ; 1.500
REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9037 ; 3.051 ; 2.000
REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 3657 ; 4.883 ; 3.000
REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3476 ; 7.835 ; 4.500
REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3
REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT
REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL
REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3
REMARK 3 NCS RESTRAINTS STATISTICS
REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : 2
REMARK 3
REMARK 3 NCS GROUP NUMBER : 1
REMARK 3 CHAIN NAMES : A C
REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 0
REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE
REMARK 3 GROUP CHAIN COUNT RMS WEIGHT
REMARK 3 TIGHT POSITIONAL 1 A (A): 2369 ; 0.13 ; 0.05
REMARK 3 TIGHT THERMAL 1 A (A**2): 2369 ; 0.50 ; 0.50
REMARK 3
REMARK 3 NCS GROUP NUMBER : 2
REMARK 3 CHAIN NAMES : B D
REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 0
REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE
REMARK 3 GROUP CHAIN COUNT RMS WEIGHT
REMARK 3 TIGHT POSITIONAL 2 B (A): 2082 ; 0.10 ; 0.05
REMARK 3 TIGHT THERMAL 2 B (A**2): 2082 ; 0.48 ; 0.50
REMARK 3
REMARK 3 TLS DETAILS
REMARK 3 NUMBER OF TLS GROUPS : NULL
REMARK 3
REMARK 3 BULK SOLVENT MODELLING.
REMARK 3 METHOD USED : BABINET MODEL WITH MASK
REMARK 3 PARAMETERS FOR MASK CALCULATION
REMARK 3 VDW PROBE RADIUS : 1.40
REMARK 3 ION PROBE RADIUS : 0.80
REMARK 3 SHRINKAGE RADIUS : 0.80
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING
REMARK 3 POSITIONS.
REMARK 4
REMARK 4 2C5O COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 30-OCT-05.
REMARK 100 THE DEPOSITION ID IS D_1290026197.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 18-NOV-02
REMARK 200 TEMPERATURE (KELVIN) : 100.0
REMARK 200 PH : 7.80
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : Y
REMARK 200 RADIATION SOURCE : ESRF
REMARK 200 BEAMLINE : ID14-2
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 0.933
REMARK 200 MONOCHROMATOR : NULL
REMARK 200 OPTICS : NULL
REMARK 200
REMARK 200 DETECTOR TYPE : CCD
REMARK 200 DETECTOR MANUFACTURER : ADSC CCD
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO
REMARK 200 DATA SCALING SOFTWARE : SCALA
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 70067
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100
REMARK 200 RESOLUTION RANGE LOW (A) : 15.000
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.600
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : 89.1
REMARK 200 DATA REDUNDANCY : 9.800
REMARK 200 R MERGE (I) : 0.10000
REMARK 200 R SYM (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 12.3000
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.10
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.15
REMARK 200 COMPLETENESS FOR SHELL (%) : 54.0
REMARK 200 DATA REDUNDANCY IN SHELL : NULL
REMARK 200 R MERGE FOR SHELL (I) : 0.41000
REMARK 200 R SYM FOR SHELL (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.800
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT
REMARK 200 SOFTWARE USED: MOLREP
REMARK 200 STARTING MODEL: PDB ENTRY 1KOU
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 49.25
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.44
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: 22% PEG 3350, 0.1M NA3-CIT, PH 7.80
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -X+1/2,-Y,Z+1/2
REMARK 290 3555 -X,Y+1/2,-Z+1/2
REMARK 290 4555 X+1/2,-Y+1/2,-Z
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.24100
REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000
REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 78.54200
REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 56.75400
REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 78.54200
REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.24100
REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 56.75400
REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1, 2
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC
REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC
REMARK 350 SOFTWARE USED: PQS
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 350
REMARK 350 BIOMOLECULE: 2
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC
REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC
REMARK 350 SOFTWARE USED: PQS
REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 400
REMARK 400 COMPOUND
REMARK 400 INVOLVED IN THE CONTROL OF THE CELL CYCLE.
REMARK 465
REMARK 465 MISSING RESIDUES
REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE
REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.)
REMARK 465
REMARK 465 M RES C SSSEQI
REMARK 465 ARG A 297
REMARK 465 LEU A 298
REMARK 465 ASN B 173
REMARK 465 GLU B 174
REMARK 465 LEU C 298
REMARK 465 ASN D 173
REMARK 465 GLU D 174
REMARK 470
REMARK 470 MISSING ATOM
REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER;
REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER;
REMARK 470 I=INSERTION CODE):
REMARK 470 M RES CSSEQI ATOMS
REMARK 470 LEU A 296 O
REMARK 470 LEU B 432 O
REMARK 470 ARG C 297 CA C O CB CG CD NE
REMARK 470 ARG C 297 CZ NH1 NH2
REMARK 470 LEU D 432 O
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT
REMARK 500
REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT.
REMARK 500
REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE
REMARK 500 OE1 GLU A 162 O HOH A 2104 1.69
REMARK 500 O HOH A 2108 O HOH A 2109 1.69
REMARK 500 N LEU A 37 O HOH A 2036 1.69
REMARK 500 O HOH D 2009 O HOH D 2050 1.73
REMARK 500 NZ LYS C 6 O HOH C 2007 1.79
REMARK 500 O VAL D 421 O HOH D 2185 1.79
REMARK 500 N MET C 1 O HOH C 2001 1.83
REMARK 500 O HOH D 2110 O HOH D 2111 1.84
REMARK 500 NE2 GLN B 317 O HOH B 2103 1.85
REMARK 500 CG2 THR C 165 O HOH C 2116 1.87
REMARK 500 CE2 TYR B 178 O HOH B 2029 1.88
REMARK 500 OG1 THR C 165 O HOH C 2115 1.91
REMARK 500 NZ LYS B 379 O HOH B 2129 1.91
REMARK 500 OD2 ASP D 345 O HOH D 2138 1.91
REMARK 500 O HOH B 2022 O HOH B 2140 1.92
REMARK 500 OE2 GLU C 162 CG2 VAL C 164 1.95
REMARK 500 O HOH A 2017 O HOH A 2052 1.96
REMARK 500 CB ASP C 247 O HOH C 2156 1.98
REMARK 500 O ASP D 345 O HOH D 2137 1.99
REMARK 500 N ASP A 38 O HOH A 2037 2.00
REMARK 500 CE2 TYR D 178 O HOH D 2036 2.01
REMARK 500 CB TYR C 15 O HOH C 2015 2.03
REMARK 500 NZ LYS D 379 O HOH D 2154 2.03
REMARK 500 O HOH C 2056 O HOH C 2059 2.03
REMARK 500 CD2 TYR B 178 O HOH A 2085 2.05
REMARK 500 OE1 GLN B 322 O HOH B 2105 2.06
REMARK 500 CB LYS D 300 O HOH D 2112 2.07
REMARK 500 O HOH C 2031 O HOH C 2069 2.08
REMARK 500 O VAL A 164 O HOH A 2106 2.09
REMARK 500 O HOH A 2029 O HOH A 2071 2.10
REMARK 500 OH TYR B 178 O HOH B 2031 2.10
REMARK 500 O HOH D 2017 O HOH D 2082 2.10
REMARK 500 CB ALA B 325 O HOH B 2105 2.10
REMARK 500 CE2 TYR B 178 O HOH A 2085 2.11
REMARK 500 OG1 THR C 160 O HOH C 2109 2.12
REMARK 500 OH TYR B 350 OD2 ASP B 393 2.12
REMARK 500 NH2 ARG C 22 O HOH C 2020 2.14
REMARK 500 NH1 ARG C 22 O HOH C 2021 2.14
REMARK 500 O TYR C 15 O HOH C 2016 2.14
REMARK 500 OH TYR B 398 O HOH B 2145 2.15
REMARK 500 OD1 ASP C 38 CB THR C 41 2.17
REMARK 500 OE2 GLU A 162 CG2 VAL A 164 2.17
REMARK 500 SG CYS D 193 O HOH D 2116 2.17
REMARK 500 CD1 PHE D 304 O HOH D 2115 2.17
REMARK 500 O LEU C 83 N7 CK2 C 1298 2.18
REMARK 500 NZ LYS B 196 O HOH B 2041 2.18
REMARK 500 CD ARG B 250 O HOH B 2069 2.19
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: CLOSE CONTACTS
REMARK 500
REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC
REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15
REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A
REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375
REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE
REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS.
REMARK 500
REMARK 500 DISTANCE CUTOFF:
REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS
REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS
REMARK 500
REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE
REMARK 500 ND2 ASN B 431 OD1 ASP C 210 2664 1.45
REMARK 500 OD2 ASP A 223 NE2 HIS C 161 2564 2.00
REMARK 500 CG ASN B 431 OD1 ASP C 210 2664 2.15
REMARK 500 O HOH A 2012 O HOH B 2146 4455 2.18
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: COVALENT BOND ANGLES
REMARK 500
REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES
REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE
REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1)
REMARK 500
REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999
REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996
REMARK 500
REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3
REMARK 500 ASP A 68 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES
REMARK 500 LEU A 76 CB - CG - CD2 ANGL. DEV. = 11.0 DEGREES
REMARK 500 ASP A 86 CB - CG - OD2 ANGL. DEV. = 5.8 DEGREES
REMARK 500 LEU A 124 CB - CG - CD2 ANGL. DEV. = -12.8 DEGREES
REMARK 500 ASP A 145 CB - CG - OD2 ANGL. DEV. = 5.8 DEGREES
REMARK 500 LEU A 202 CB - CG - CD2 ANGL. DEV. = 10.5 DEGREES
REMARK 500 VAL A 230 CB - CA - C ANGL. DEV. = -12.2 DEGREES
REMARK 500 ASP A 235 CB - CG - OD2 ANGL. DEV. = 8.0 DEGREES
REMARK 500 ASP A 258 CB - CG - OD1 ANGL. DEV. = 6.1 DEGREES
REMARK 500 ASP A 270 CB - CG - OD2 ANGL. DEV. = 5.9 DEGREES
REMARK 500 ASP B 205 CB - CG - OD2 ANGL. DEV. = 8.4 DEGREES
REMARK 500 ASP B 240 CB - CG - OD2 ANGL. DEV. = 6.4 DEGREES
REMARK 500 ARG B 241 NE - CZ - NH2 ANGL. DEV. = -4.3 DEGREES
REMARK 500 ASP B 284 CB - CG - OD2 ANGL. DEV. = 5.9 DEGREES
REMARK 500 THR B 316 OG1 - CB - CG2 ANGL. DEV. = -14.3 DEGREES
REMARK 500 ASP B 345 CB - CG - OD2 ANGL. DEV. = 8.0 DEGREES
REMARK 500 ARG C 126 NE - CZ - NH2 ANGL. DEV. = -4.0 DEGREES
REMARK 500 ARG C 150 NE - CZ - NH1 ANGL. DEV. = 7.1 DEGREES
REMARK 500 ASP C 210 CB - CG - OD2 ANGL. DEV. = 6.1 DEGREES
REMARK 500 ASP C 235 CB - CG - OD2 ANGL. DEV. = 7.2 DEGREES
REMARK 500 ARG C 245 NE - CZ - NH2 ANGL. DEV. = -3.5 DEGREES
REMARK 500 ASP C 270 CB - CG - OD1 ANGL. DEV. = 6.1 DEGREES
REMARK 500 ARG D 187 NE - CZ - NH2 ANGL. DEV. = -3.1 DEGREES
REMARK 500 ASP D 205 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES
REMARK 500 ARG D 241 NE - CZ - NH1 ANGL. DEV. = 4.1 DEGREES
REMARK 500 ARG D 241 NE - CZ - NH2 ANGL. DEV. = -4.4 DEGREES
REMARK 500 ASP D 283 CB - CG - OD2 ANGL. DEV. = 5.7 DEGREES
REMARK 500 ASP D 284 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES
REMARK 500 THR D 285 OG1 - CB - CG2 ANGL. DEV. = -14.0 DEGREES
REMARK 500 ASP D 343 CB - CG - OD2 ANGL. DEV. = 7.3 DEGREES
REMARK 500 ASP D 345 CB - CG - OD2 ANGL. DEV. = 8.7 DEGREES
REMARK 500 ASP D 393 CB - CG - OD2 ANGL. DEV. = 8.4 DEGREES
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 TYR A 15 -38.40 78.73
REMARK 500 VAL A 17 120.48 6.08
REMARK 500 THR A 41 -104.80 -80.47
REMARK 500 LEU A 96 -60.85 97.39
REMARK 500 ARG A 126 -18.17 76.97
REMARK 500 ASP A 145 80.78 58.56
REMARK 500 THR A 160 -72.04 -28.94
REMARK 500 VAL A 163 35.52 -99.47
REMARK 500 THR A 290 -161.57 -123.85
REMARK 500 PRO B 176 150.94 -48.91
REMARK 500 ASP B 177 3.45 -64.50
REMARK 500 ASP B 283 40.28 75.48
REMARK 500 THR B 303 42.16 37.25
REMARK 500 ASP B 345 -76.57 48.44
REMARK 500 TRP B 372 112.03 -23.91
REMARK 500 HIS B 419 29.82 49.59
REMARK 500 LEU B 424 155.15 -37.35
REMARK 500 TYR C 15 -38.02 78.20
REMARK 500 VAL C 17 128.13 5.60
REMARK 500 THR C 41 -112.57 -82.35
REMARK 500 LEU C 96 -61.25 98.78
REMARK 500 ARG C 126 -18.24 82.92
REMARK 500 ASP C 145 72.75 57.45
REMARK 500 THR C 160 -70.39 -34.83
REMARK 500 VAL C 163 39.31 -95.84
REMARK 500 THR C 290 -154.39 -119.30
REMARK 500 LYS C 291 58.83 -147.22
REMARK 500 PRO D 176 154.63 -44.57
REMARK 500 ASP D 345 -87.18 33.45
REMARK 500 TRP D 372 108.72 -25.42
REMARK 500 LEU D 424 150.46 -46.11
REMARK 500 ASN D 431 46.47 70.69
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS
REMARK 500
REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH
REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED
REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND
REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES.
REMARK 500 MODEL OMEGA
REMARK 500 TYR A 15 GLY A 16 142.85
REMARK 500 GLY A 16 VAL A 17 -137.98
REMARK 500 ILE A 70 HIS A 71 -149.84
REMARK 500 VAL B 175 PRO B 176 -149.24
REMARK 500 ALA B 344 ASP B 345 127.22
REMARK 500 ASP B 345 PRO B 346 136.74
REMARK 500 TYR C 15 GLY C 16 148.15
REMARK 500 GLY C 16 VAL C 17 -134.80
REMARK 500 ILE C 70 HIS C 71 -149.06
REMARK 500 VAL D 175 PRO D 176 -146.80
REMARK 500 ALA D 344 ASP D 345 135.00
REMARK 500 ASP D 345 PRO D 346 146.52
REMARK 500
REMARK 500 REMARK: NULL
REMARK 525
REMARK 525 SOLVENT
REMARK 525
REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT
REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST
REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT
REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE
REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER;
REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE
REMARK 525 NUMBER; I=INSERTION CODE):
REMARK 525
REMARK 525 M RES CSSEQI
REMARK 525 HOH A2062 DISTANCE = 5.90 ANGSTROMS
REMARK 525 HOH B2001 DISTANCE = 7.27 ANGSTROMS
REMARK 525 HOH D2003 DISTANCE = 6.42 ANGSTROMS
REMARK 525 HOH D2004 DISTANCE = 7.04 ANGSTROMS
REMARK 525 HOH D2020 DISTANCE = 5.83 ANGSTROMS
REMARK 800
REMARK 800 SITE
REMARK 800 SITE_IDENTIFIER: AC1
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CK2 A1297
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC2
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CK2 C1298
REMARK 900
REMARK 900 RELATED ENTRIES
REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR
REMARK 900 STAUROSPORINE
REMARK 900 RELATED ID: 1B38 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2
REMARK 900 RELATED ID: 1B39 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
REMARK 900 RELATED ID: 1BUH RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-
REMARK 900 REGULATORY PROTEIN CKSHS1
REMARK 900 RELATED ID: 1CKP RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR
REMARK 900 PURVALANOL B
REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-
REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE
REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR
REMARK 900 HYMENIALDISINE
REMARK 900 RELATED ID: 1E1V RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
REMARK 900 RELATED ID: 1E1X RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
REMARK 900 RELATED ID: 1E9H RELATED DB: PDB
REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE
REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND
REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO
REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2
REMARK 900 RELATED ID: 1FIN RELATED DB: PDB
REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX
REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX
REMARK 900 WITH PHOSPHO-CDK2
REMARK 900 RELATED ID: 1FVT RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN
REMARK 900 OXINDOLE INHIBITOR
REMARK 900 RELATED ID: 1FVV RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR
REMARK 900 RELATED ID: 1G5S RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN
REMARK 900 COMPLEX WITH THE INHIBITOR H717
REMARK 900 RELATED ID: 1GIH RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
REMARK 900 RELATED ID: 1GII RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR
REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB
REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE
REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-
REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE
REMARK 900 RELATED ID: 1H00 RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE
REMARK 900 CDK4 INHIBITOR
REMARK 900 RELATED ID: 1H01 RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE
REMARK 900 CDK4 INHIBITOR
REMARK 900 RELATED ID: 1H07 RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE
REMARK 900 CDK4 INHIBITOR
REMARK 900 RELATED ID: 1H08 RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE
REMARK 900 CDK4 INHIBITOR
REMARK 900 RELATED ID: 1H0V RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE
REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE
REMARK 900 RELATED ID: 1H0W RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE
REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE
REMARK 900 RELATED ID: 1H1P RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE
REMARK 900 INHIBITOR NU2058
REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE
REMARK 900 INHIBITOR NU6094
REMARK 900 RELATED ID: 1H1R RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE
REMARK 900 INHIBITOR NU6086
REMARK 900 RELATED ID: 1H1S RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE
REMARK 900 INHIBITOR NU6102
REMARK 900 RELATED ID: 1H24 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM
REMARK 900 E2F
REMARK 900 RELATED ID: 1H25 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM
REMARK 900 E2F
REMARK 900 RELATED ID: 1H26 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM
REMARK 900 P53
REMARK 900 RELATED ID: 1H27 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM
REMARK 900 P27
REMARK 900 RELATED ID: 1H28 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM
REMARK 900 P107
REMARK 900 RELATED ID: 1HCK RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2
REMARK 900 RELATED ID: 1HCL RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2
REMARK 900 RELATED ID: 1JST RELATED DB: PDB
REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
REMARK 900 RELATED ID: 1JSU RELATED DB: PDB
REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX
REMARK 900 RELATED ID: 1JSV RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-
REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE
REMARK 900 RELATED ID: 1JVP RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH
REMARK 900 PKF049-365
REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB
REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3-
REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE
REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB
REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-
REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO]
REMARK 900 PHENYL}METHANESULFONAMIDE
REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB
REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,
REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)-
REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE
REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB
REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-
REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL)
REMARK 900 BENZENESULFONAMIDE
REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB
REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({
REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-
REMARK 900 DIHYDRO-1H-INDOLE
REMARK 900 RELATED ID: 1OGU RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2-
REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6-
REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB
REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT
REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
REMARK 900 RELATED ID: 1OIR RELATED DB: PDB
REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT
REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
REMARK 900 RELATED ID: 1OIT RELATED DB: PDB
REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT
REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
REMARK 900 RELATED ID: 1OIU RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6-
REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
REMARK 900 RELATED ID: 1OIY RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6-
REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
REMARK 900 RELATED ID: 1OKU RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU-ILE-(P-
REMARK 900 F-PHE)-NH2
REMARK 900 RELATED ID: 1OKV RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2
REMARK 900 RELATED ID: 1OKW RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2
REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2
REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2
REMARK 900 RELATED ID: 1P2A RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH
REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
REMARK 900 RELATED ID: 1P5E RELATED DB: PDB
REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR
REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS)
REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH
REMARK 900 A NUCLEOSIDE INHIBITOR
REMARK 900 RELATED ID: 1PKD RELATED DB: PDB
REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN
REMARK 900 A
REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB
REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
REMARK 900 RELATED ID: 1PXI RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5-
REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE
REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4-
REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE
REMARK 900 RELATED ID: 1PXK RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,
REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE
REMARK 900 RELATED ID: 1PXL RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4-
REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)-
REMARK 900 AMINE
REMARK 900 RELATED ID: 1PXM RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2,
REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL
REMARK 900 RELATED ID: 1PXN RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4-
REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
REMARK 900 RELATED ID: 1PXO RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2-
REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)-
REMARK 900 AMINE
REMARK 900 RELATED ID: 1PXP RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,
REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1,
REMARK 900 4-DIAMINE
REMARK 900 RELATED ID: 1PYE RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB
REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
REMARK 900 RELATED ID: 1R78 RELATED DB: PDB
REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
REMARK 900 RELATED ID: 1URC RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2
REMARK 900 RELATED ID: 1URW RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE
REMARK 900 RELATED ID: 1V1K RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE
REMARK 900 CDK4 INHIBITOR
REMARK 900 RELATED ID: 1VYW RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
REMARK 900 RELATED ID: 1W0X RELATED DB: PDB
REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR
REMARK 900 OLOMOUCINE.
REMARK 900 RELATED ID: 1W8C RELATED DB: PDB
REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2-
REMARK 900 YLAMINE AND MONOMERIC CDK2
REMARK 900 RELATED ID: 1W98 RELATED DB: PDB
REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
REMARK 900 RELATED ID: 1WCC RELATED DB: PDB
REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]
REMARK 900 PYRIMIDINE INHIBITOR
REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]
REMARK 900 PYRIMIDINE INHIBITOR
REMARK 900 RELATED ID: 2B52 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562
REMARK 900 RELATED ID: 2B53 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325
REMARK 900 RELATED ID: 2B54 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305
REMARK 900 RELATED ID: 2B55 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE
REMARK 900 DIN-101312
REMARK 900 RELATED ID: 2BHE RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE
REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE
REMARK 900 RELATED ID: 2BHH RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE
REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE
REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
REMARK 900 RELATED ID: 2BPM RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
REMARK 900 RELATED ID: 2BTR RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
REMARK 900 RELATED ID: 2BTS RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
REMARK 900 RELATED ID: 2C4G RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
REMARK 900 RELATED ID: 2C5N RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2
REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN
REMARK 900 RELATED ID: 2C5P RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2
REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN
REMARK 900 RELATED ID: 2C5T RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2
REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN
REMARK 900 RELATED ID: 2C5X RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2
REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN
REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2
REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN
DBREF 2C5O A 1 298 UNP P24941 CDK2_HUMAN 1 298
DBREF 2C5O B 173 432 UNP P20248 CCNA2_HUMAN 173 432
DBREF 2C5O C 1 298 UNP P24941 CDK2_HUMAN 1 298
DBREF 2C5O D 173 432 UNP P20248 CCNA2_HUMAN 173 432
SEQRES 1 A 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY
SEQRES 2 A 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR
SEQRES 3 A 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR
SEQRES 4 A 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE
SEQRES 5 A 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS
SEQRES 6 A 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU
SEQRES 7 A 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET
SEQRES 8 A 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE
SEQRES 9 A 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE
SEQRES 10 A 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO
SEQRES 11 A 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU
SEQRES 12 A 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL
SEQRES 13 A 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG
SEQRES 14 A 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR
SEQRES 15 A 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU
SEQRES 16 A 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU
SEQRES 17 A 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR
SEQRES 18 A 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO
SEQRES 19 A 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP
SEQRES 20 A 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG
SEQRES 21 A 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS
SEQRES 22 A 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE
SEQRES 23 A 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU
SEQRES 1 B 260 ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR
SEQRES 2 B 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY
SEQRES 3 B 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG
SEQRES 4 B 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU
SEQRES 5 B 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN
SEQRES 6 B 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG
SEQRES 7 B 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU
SEQRES 8 B 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA
SEQRES 9 B 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS
SEQRES 10 B 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU
SEQRES 11 B 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU
SEQRES 12 B 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS
SEQRES 13 B 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU
SEQRES 14 B 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL
SEQRES 15 B 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL
SEQRES 16 B 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR
SEQRES 17 B 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP
SEQRES 18 B 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN
SEQRES 19 B 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS
SEQRES 20 B 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU
SEQRES 1 C 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY
SEQRES 2 C 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR
SEQRES 3 C 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR
SEQRES 4 C 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE
SEQRES 5 C 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS
SEQRES 6 C 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU
SEQRES 7 C 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET
SEQRES 8 C 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE
SEQRES 9 C 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE
SEQRES 10 C 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO
SEQRES 11 C 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU
SEQRES 12 C 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL
SEQRES 13 C 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG
SEQRES 14 C 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR
SEQRES 15 C 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU
SEQRES 16 C 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU
SEQRES 17 C 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR
SEQRES 18 C 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO
SEQRES 19 C 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP
SEQRES 20 C 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG
SEQRES 21 C 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS
SEQRES 22 C 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE
SEQRES 23 C 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU
SEQRES 1 D 260 ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR
SEQRES 2 D 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY
SEQRES 3 D 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG
SEQRES 4 D 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU
SEQRES 5 D 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN
SEQRES 6 D 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG
SEQRES 7 D 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU
SEQRES 8 D 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA
SEQRES 9 D 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS
SEQRES 10 D 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU
SEQRES 11 D 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU
SEQRES 12 D 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS
SEQRES 13 D 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU
SEQRES 14 D 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL
SEQRES 15 D 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL
SEQRES 16 D 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR
SEQRES 17 D 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP
SEQRES 18 D 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN
SEQRES 19 D 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS
SEQRES 20 D 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU
HET CK2 A1297 28
HET CK2 C1298 28
HETNAM CK2 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE
HETSYN CK2 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
FORMUL 5 CK2 2(C9 H10 N4 S)
FORMUL 7 HOH *725(H2 O)
HELIX 1 1 PRO A 45 LYS A 56 1 12
HELIX 2 2 LEU A 87 SER A 94 1 8
HELIX 3 3 PRO A 100 HIS A 121 1 22
HELIX 4 4 LYS A 129 GLN A 131 5 3
HELIX 5 5 ALA A 170 LEU A 175 1 6
HELIX 6 6 THR A 182 ARG A 199 1 18
HELIX 7 7 SER A 207 GLY A 220 1 14
HELIX 8 8 GLY A 229 MET A 233 5 5
HELIX 9 9 ASP A 247 VAL A 252 1 6
HELIX 10 10 ASP A 256 LEU A 267 1 12
HELIX 11 11 SER A 276 HIS A 283 1 8
HELIX 12 12 PRO A 284 GLN A 287 5 4
HELIX 13 13 TYR B 178 CYS B 193 1 16
HELIX 14 14 GLY B 198 GLN B 203 1 6
HELIX 15 15 THR B 207 TYR B 225 1 19
HELIX 16 16 GLN B 228 MET B 246 1 19
HELIX 17 17 LYS B 252 GLU B 269 1 18
HELIX 18 18 GLU B 274 ILE B 281 1 8
HELIX 19 19 THR B 287 LEU B 302 1 16
HELIX 20 20 THR B 310 PHE B 319 1 10
HELIX 21 21 LEU B 320 GLN B 322 5 3
HELIX 22 22 ASN B 326 ASP B 343 1 18
HELIX 23 23 ASP B 343 LEU B 348 1 6
HELIX 24 24 LEU B 351 GLY B 369 1 19
HELIX 25 25 PRO B 373 GLY B 381 1 9
HELIX 26 26 LEU B 387 ALA B 401 1 15
HELIX 27 27 PRO B 402 HIS B 404 5 3
HELIX 28 28 GLN B 407 TYR B 413 1 7
HELIX 29 29 LYS B 414 HIS B 419 5 6
HELIX 30 30 PRO C 45 LEU C 58 1 14
HELIX 31 31 LEU C 87 SER C 94 1 8
HELIX 32 32 PRO C 100 HIS C 121 1 22
HELIX 33 33 LYS C 129 GLN C 131 5 3
HELIX 34 34 ALA C 170 LEU C 175 1 6
HELIX 35 35 THR C 182 ARG C 199 1 18
HELIX 36 36 SER C 207 GLY C 220 1 14
HELIX 37 37 GLY C 229 MET C 233 5 5
HELIX 38 38 ASP C 247 VAL C 252 1 6
HELIX 39 39 ASP C 256 LEU C 267 1 12
HELIX 40 40 SER C 276 HIS C 283 1 8
HELIX 41 41 PRO C 284 VAL C 289 5 6
HELIX 42 42 TYR D 178 CYS D 193 1 16
HELIX 43 43 GLY D 198 LYS D 202 5 5
HELIX 44 44 THR D 207 TYR D 225 1 19
HELIX 45 45 GLN D 228 SER D 244 1 17
HELIX 46 46 LYS D 252 GLU D 269 1 18
HELIX 47 47 GLU D 274 ILE D 281 1 8
HELIX 48 48 THR D 287 LEU D 302 1 16
HELIX 49 49 THR D 310 PHE D 319 1 10
HELIX 50 50 LEU D 320 GLN D 322 5 3
HELIX 51 51 ASN D 326 ASP D 343 1 18
HELIX 52 52 ASP D 343 LEU D 348 1 6
HELIX 53 53 LEU D 351 GLY D 369 1 19
HELIX 54 54 PRO D 373 GLY D 381 1 9
HELIX 55 55 LEU D 387 ALA D 401 1 15
HELIX 56 56 PRO D 402 HIS D 404 5 3
HELIX 57 57 GLN D 407 LYS D 414 1 8
HELIX 58 58 ASN D 415 HIS D 419 5 5
SHEET 1 AA 5 PHE A 4 GLY A 11 0
SHEET 2 AA 5 VAL A 18 ASN A 23 -1 O VAL A 18 N ILE A 10
SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21
SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35
SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79
SHEET 1 AB 3 GLN A 85 ASP A 86 0
SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85
SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134
SHEET 1 AC 2 VAL A 123 LEU A 124 0
SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124
SHEET 1 CA 5 PHE C 4 GLY C 11 0
SHEET 2 CA 5 VAL C 18 ASN C 23 -1 O VAL C 18 N ILE C 10
SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21
SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35
SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79
SHEET 1 CB 3 GLN C 85 ASP C 86 0
SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85
SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134
SHEET 1 CC 2 VAL C 123 LEU C 124 0
SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124
CISPEP 1 GLN B 323 PRO B 324 0 -9.54
CISPEP 2 GLN D 323 PRO D 324 0 -8.44
SITE 1 AC1 9 ILE A 10 ALA A 31 LYS A 33 GLU A 81
SITE 2 AC1 9 PHE A 82 LEU A 83 LEU A 134 HOH A2030
SITE 3 AC1 9 HOH A2093
SITE 1 AC2 10 GLU C 12 VAL C 18 ALA C 31 LYS C 33
SITE 2 AC2 10 GLU C 81 PHE C 82 LEU C 83 LEU C 134
SITE 3 AC2 10 ASP C 145 HOH C2048
CRYST1 74.482 113.508 157.084 90.00 90.00 90.00 P 21 21 21 8
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.013426 0.000000 0.000000 0.00000
SCALE2 0.000000 0.008810 0.000000 0.00000
SCALE3 0.000000 0.000000 0.006366 0.00000